Maxim Group Analysts Reduce Earnings Estimates for KindlyMD

Key Points

• Maxim Group lowered its Q3 2026 EPS estimate for KindlyMD to a loss of $0.49 per share from a previous loss estimate of $0.43. The firm projects additional losses through 2027, including a full-year 2027 loss of $2.12 per share.
• Analyst sentiment is mixed, with KindlyMD carrying a consensus “Hold” rating and a $22.33 price target. Recent ratings include a “Sell” from Weiss Ratings and a “Buy” from TD Cowen, which raised its target to $17.
• KindlyMD reported a quarterly loss of $6.65 per share on $35.87 million in revenue, alongside sharply negative profitability metrics. Shares opened at $6.30, while insiders have purchased about 196,366 shares over the past three months.

KindlyMD, Inc. (NASDAQ:NAKA - Free Report) - Equities research analysts at Maxim Group dropped their Q3 2026 earnings per share (EPS) estimates for KindlyMD in a research note issued on Wednesday, August 19th. Maxim Group analyst M. Galinko now forecasts that the company will post earnings of ($0.49) per share for the quarter, down from their previous estimate of ($0.43). The consensus estimate for KindlyMD's current full-year earnings is ($11.31) per share. Maxim Group also issued estimates for KindlyMD's Q4 2026 earnings at ($0.48) EPS, Q1 2027 earnings at ($0.76) EPS, Q2 2027 earnings at ($0.74) EPS, Q3 2027 earnings at ($0.20) EPS, Q4 2027 earnings at ($0.43) EPS and FY2027 earnings at ($2.12) EPS.

Several other research analysts have also recently weighed in on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of KindlyMD in a report on Friday, August 7th. Wall Street Zen upgraded KindlyMD to a "sell" rating in a report on Saturday, May 23rd. Finally, TD Cowen lifted their target price on KindlyMD from $1.00 to $17.00 and gave the company a "buy" rating in a research report on Monday, July 27th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $22.33.

KindlyMD Stock Performance

NASDAQ NAKA opened at $6.30 on Friday. The business has a 50 day simple moving average of $4.48 and a 200 day simple moving average of $7.24. KindlyMD has a 52-week low of $3.33 and a 52-week high of $432.40. The stock has a market cap of $112.77 million, a price-to-earnings ratio of -0.18 and a beta of 15.95.

KindlyMD (NASDAQ:NAKA - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($6.65) EPS for the quarter. KindlyMD had a negative return on equity of 63.45% and a negative net margin of 1,067.93%.The business had revenue of $35.87 million for the quarter.

Insider Buying and Selling at KindlyMD

In related news, CEO David F. Bailey bought 104,833 shares of the stock in a transaction that occurred on Wednesday, May 27th. The shares were acquired at an average price of $4.84 per share, with a total value of $507,391.72. Following the completion of the transaction, the chief executive officer owned 3,120,361 shares in the company, valued at $15,102,547.24. The trade was a 3.48% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders bought 196,366 shares of company stock valued at $1,018,088. 24.49% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Alyeska Investment Group L.P. acquired a new stake in shares of KindlyMD in the 4th quarter valued at approximately $8,993,000. ParaFi Capital LP bought a new stake in KindlyMD during the third quarter worth $443,055,000. Hunting Hill Global Capital LLC acquired a new stake in KindlyMD in the fourth quarter valued at $4,672,000. Yorkville Advisors Global LP acquired a new stake in KindlyMD in the fourth quarter valued at $3,265,000. Finally, UBS Group AG bought a new position in shares of KindlyMD in the 4th quarter valued at about $2,958,000.

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source